Online citations, reference lists, and bibliographies.
← Back to Search

Challenges And Solutions For The Delivery Of Biotech Drugs--a Review Of Drug Nanocrystal Technology And Lipid Nanoparticles.

R. H. Muller, C. Keck
Published 2004 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Biotechnology allows tailor-made production of biopharmaceuticals and biotechnological drugs; however, many of them require special formulation technologies to overcome drug-associated problems. Such potential challenges to solve are: poor solubility, limited chemical stability in vitro and in vivo after administration (i.e. short half-life), poor bioavailability and potentially strong side effects requiring drug enrichment at the site of action (targeting). This review describes the use of nanoparticulate carriers, developed in our research group, as one solution to overcome such delivery problems, i.e. drug nanocrystals, solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC) and lipid-drug conjugate (LDC) nanoparticles, examples of drugs are given. As a recently developed targeting principle, the concept of differential protein adsorption is described (PathFinder Technology) using as example delivery to the brain.
This paper references
10.1002/1520-6017(200008)89:8<967::AID-JPS1>3.0.CO;2-R
Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts.
W. Charman (2000)
10.1016/S0939-6411(02)00165-0
Pharmaceutical biotechnology products approved within the European Union.
G. Walsh (2003)
10.1016/S0169-409X(02)00118-7
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations.
R. Mueller (2002)
10.1128/AAC.45.6.1771-1779.2001
Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis
N. Schöler (2001)
10.1111/j.2042-7158.1979.tb13510.x
Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties
P. Couvreur (1979)
Bioadhesion: Possibilities and Future Trends
R. Gurny (1990)
10.1016/S0939-6411(03)00063-8
Intravenous itraconazole emulsions produced by SolEmuls technology.
A. Akkar (2003)
10.2165/00003088-199223040-00004
Liposomal and Lipid Formulations of Amphotericin B
R. Janknegt (1992)
10.1016/S0378-5173(99)00414-7
Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation.
K. Krause (2000)
10.1007/s001250051618
Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients
G. Brunner (2001)
10.1016/S0168-3659(98)00030-3
Plasma protein adsorption on biodegradable microspheres consisting of poly(D,L-lactide-co-glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene). Influence of production method and polymer composition.
M. Lück (1998)
10.1016/0378-5173(95)00148-C
Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats
G. Liversidge (1995)
10.1021/BC970025W
New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability.
S. Arpicco (1997)
Nanoparticles and nanocapsules--new dosage forms in the nanometer size range.
J. Kreuter (1978)
10.1007/BF02030131
Verteilung und Elimination mittel- und langkettiger Fettsäuren einer Fettemulsion in den Lipoproteinen schwerverletzter Patienten nach Bolusinjektion
G. Wolfram (1989)
10.1016/0014-4827(83)90197-0
Receptor-mediated particle uptake by liver macrophages. The galactose-particle receptor mediates uptake via coated and also non-coated structures.
V. Kolb-Bachofen (1983)
10.1023/A:1011928415808
Stability of Alkoxycarbonylamidine Prodrugs
Z. Shahrokh (2004)
10.1128/AAC.44.6.1463-1469.2000
Antifungal Activity of Amphotericin B Cochleates against Candida albicans Infection in a Mouse Model
L. Zarif (2000)
10.1128/AAC.42.2.459
Rationale for and Efficacy of Prolonged-Interval Treatment Using Liposome-Encapsulated Amikacin in Experimental Mycobacterium avium Infection
S. Leitzke (1998)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1211/0022357021771896
Evaluation of the in‐vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products
L. Sek (2002)
10.1016/S0378-5173(99)00434-2
Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages.
O. Kayser (2000)
Hydrosols : alternatives for the parenteral application of poorly water soluble drugs
P. Gassmann (1994)
10.1200/JCO.1995.13.4.996
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
P. Gill (1995)
10.1016/0014-4827(88)90118-8
Binding, uptake, and transcytosis of ligands for mannose-specific receptors in rat liver: an electron microscopic study.
G. Kempka (1988)
[New drug formulations as the result of recent technological development efforts].
P. Speiser (1973)
10.1016/S0169-409X(01)00182-X
In vitro assessment of oral lipid based formulations.
C. J. Porter (2001)
10.1023/A:1011032328064
Size-Dependent Bioadhesion of Micro- and Nanoparticulate Carriers to the Inflamed Colonic Mucosa
A. Lamprecht (2004)
10.1016/S0939-6411(97)00098-2
Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract
G. Ponchel (1997)
10.3109/02652049809006836
Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study.
R. Alyautdin (1998)
10.1093/JAC/39.5.655
The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures.
Y. Shadkhan (1997)
10.1016/S0378-5173(00)00639-6
The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles.
A. Gessner (2001)
10.1016/0005-2736(89)90307-6
Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes.
S. Moghimi (1989)
10.1016/0378-5173(95)00122-Y
Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs
G. Liversidge (1995)
10.1038/nbt0803-865
Biopharmaceutical benchmarks—2003
G. Walsh (2003)
10.1016/S0076-6879(86)32015-9
[13] Opsonins and dysopsonins: An overview
D. Absolom (1986)
10.1016/S0169-409X(00)00120-4
Mucoadhesive nanoparticulate systems for peptide drug delivery.
H. Takeuchi (2001)
10.1016/S0378-5173(02)00686-5
Formulation of amphotericin B as nanosuspension for oral administration.
O. Kayser (2003)
Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles
R. Alyautdin (1995)
10.1016/S0005-2736(97)00177-6
Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin.
G. Cevc (1998)
10.1016/0024-3205(87)90138-X
The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908.
L. Illum (1987)
10.1093/OXFORDJOURNALS.BMB.A070612
Ultrastructure of membranes: biomolecular organization.
Bangham Ad (1968)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.2337/DIACARE.23.9.1343
Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer.
L. Heinemann (2000)
10.1136/bmj.317.7155.379
Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study
P. Schöffski (1998)
10.1016/0165-6147(94)90314-X
Long-circulating (sterically stabilized) liposomes for targeted drug delivery.
T. Allen (1994)
10.1016/0167-4889(93)90137-E
Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum.
S. Moghimi (1993)
10.1016/S0378-5173(99)00050-2
Studies on the uptake of tomato lectin nanoparticles in everted gut sacs.
B. Carreño-Gómez (1999)
10.1201/9781482289985
Handbook of Pharmaceutical Controlled Release Technology
D. Wise (2000)
10.1016/0009-3084(93)90071-A
Liposomes: the Babraham connection.
A. Bangham (1993)
10.1023/A:1021410028371
Dissolution Rate Enhancement by in Situ Micronization of Poorly Water-Soluble Drugs
N. Rasenack (2004)
10.1021/J100358A010
Cubic lipid-water phases: structures and biomembrane aspects
K. Larsson (1989)
10.1016/S0142-9612(99)00110-6
Complement activation by model drug carriers for intravenous application: determination by two-dimensional electrophoresis.
M. Lück (1999)
Nanoparticles--a new colloidal drug delivery system.
J. Marty (1978)
10.1016/S0731-7085(00)00528-8
Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis.
L. Sek (2001)
Solid lipid nanoparticles (SLN) : an alternative colloidal carrier system for controlled drug delivery
R. Mueller (1995)
10.1177/014860718000400405
Fat emulsions containing medium chain triglycerides in parenteral nutrition of intensive care patients.
J. Eckart (1980)
10.1016/S1054-3589(08)60246-X
Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents.
K. Widder (1979)
10.1038/380561A0
Doxorubicin in sterically stabilized liposomes
D. Lasic (1996)



This paper is referenced by
10.4172/2572-0813.1000112
Exploring the Use of Lipid Based Nano-Formulations for the Management of Tuberculosis
Bibhas Cm (2017)
10.1517/17425247.5.1.69
Past and future evolution in colloidal drug delivery systems
B. Boyd (2008)
10.1098/rsfs.2015.0086
Cell and nanoparticle transport in tumour microvasculature: the role of size, shape and surface functionality of nanoparticles
Y. Li (2016)
10.1007/978-981-10-5511-9_15
Nanomaterial-Enabled Immunotherapeutic Applications
Reena V. Saini (2017)
10.2147/NANO.2007.2.1.25
Nanomedicines in renal transplant rejection – focus on sirolimus
L. Shen (2007)
10.1208/s12249-010-9438-4
Dissolution Improvement of Electrospun Nanofiber-Based Solid Dispersions for Acetaminophen
Deng-Guang Yu (2010)
10.15226/2376-4589/2/2/00115
Vaccines against Pathogens: A Review and Food For Thought
A. A. Amara (2016)
10.7282/T3BZ6506
Interfacial interactions of nanoparticles with surfactants and polymers: A computational approach to target biomedical and pharmaceutical systems
Michael D. Tomasini (2012)
10.1007/s13205-017-0986-0
Nanoformulation of Leonotis leonurus to improve its bioavailability as a potential antidiabetic drug
F. Odei-Addo (2017)
10.1055/s-0043-106051
Preparation and Characterization of Copolymeric Polymersomes for Protein Delivery.
A. Nomani (2017)
10.3389/fphar.2020.00487
Nanocurcumin: A Promising Candidate for Therapeutic Applications
A. Karthikeyan (2020)
10.1039/c8sm01304g
Shear rate dependent margination of sphere-like, oblate-like and prolate-like micro-particles within blood flow.
Huilin Ye (2018)
10.1016/B978-0-12-415769-9.00014-5
Nanocarriers as Nanomedicines: Design Concepts and Recent Advances
V. Grazú (2012)
10.1002/jps.22335
Fabrication of paclitaxel nanocrystals by femtosecond laser ablation and fragmentation.
S. Kenth (2011)
10.1016/j.actbio.2011.06.015
Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy.
P. Parhi (2011)
10.1201/9781420008449.CH5
Drug Nanocrystals—The Universal Formulation Approach for Poorly Soluble Drugs
J. Möschwitzer (2007)
10.1016/j.neurol.2008.03.015
[Local chemotherapy of malignant glioma: from syringe injections to nanotechnology].
S. Petit (2008)
10.1016/j.ijpharm.2009.04.038
Advantages of celecoxib nanosuspension formulation and transformation into tablets.
Andrej Dolenc (2009)
10.1007/978-3-642-00477-3_4
Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes.
E. Souto (2010)
10.1016/J.SUPFLU.2006.01.014
Solubility of carbon dioxide in three lipid-based biocarriers
A. R. Sousa (2006)
10.1016/J.CIS.2006.05.014
Microemulsions as transdermal drug delivery vehicles.
A. Kogan (2006)
10.1016/J.TUBE.2005.08.009
Oral solid lipid nanoparticle-based antitubercular chemotherapy.
R. Pandey (2005)
10.1208/s12249-010-9561-2
Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents
Anumita Chaudhury (2010)
10.3390/molecules24071421
Nanocrystallization of Anthocyanin Extract from Red-Fleshed Apple ′QN-5′ Improved Its Antioxidant Effect through Enhanced Stability and Activity under Stressful Conditions
X. Zhang (2019)
10.1007/s10965-019-1901-7
Synthesis, characterization, toxicity and in vivo imaging of lysine graft polymeric nanoparticles
B. Bakan (2019)
10.1016/j.xphs.2017.06.006
Incomplete Loading of Sodium Lauryl Sulfate and Fasted State Simulated Intestinal Fluid Micelles Within the Diffusion Layers of Dispersed Drug Particles During Dissolution.
Kendra Galipeau (2018)
10.1016/j.biotechadv.2013.10.002
Nanoparticles containing insoluble drug for cancer therapy.
S. Guo (2014)
EFFECT OF ARTEMISININ LIPOSOME AND ARTEMISININ LIPOSOME POLYETHYLENE GLYCOL ON MCF-7 CELL LINE
Dadgar Neda (2006)
10.1002/jps.23087
Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation.
G. Kumar (2012)
10.1002/cmdc.201600090
Acyclic Cucurbit[n]uril‐Type Molecular Containers: Influence of Linker Length on Their Function as Solubilizing Agents
David Sigwalt (2016)
10.5772/36672
Electrospray Production of Nanoparticles for Drug/Nucleic Acid Delivery
Y. Wu (2012)
10.1039/C6TB00900J
How can nanomedicines overcome cellular-based anticancer drug resistance?
D. Sobot (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar